Figure 2
Figure 2. Propranolol, a PAP inhibitor, but not RHC 80267, a DAG lipase inhibitor, blocks VEGF-induced HRMVEC DNA synthesis, migration, and tube formation. (A-C) All the conditions were the same as in Figure 1B, C, and D, respectively, except that either propranolol (200μM) or RHC80267 (50μM) was added to cells 30 minutes before treatment with and without VEGF. Values are mean ± SD. *P < .01 versus vehicle control. **P < .01 versus VEGF.

Propranolol, a PAP inhibitor, but not RHC 80267, a DAG lipase inhibitor, blocks VEGF-induced HRMVEC DNA synthesis, migration, and tube formation. (A-C) All the conditions were the same as in Figure 1B, C, and D, respectively, except that either propranolol (200μM) or RHC80267 (50μM) was added to cells 30 minutes before treatment with and without VEGF. Values are mean ± SD. *P < .01 versus vehicle control. **P < .01 versus VEGF.

Close Modal

or Create an Account

Close Modal
Close Modal